Baseline characteristics of survivors and non-survivors
| Variables | Survivors (n=1716) | Non–survivors (n=311) | P value |
| Age (years) | 66.9±13.8 | 74.0±13.1 | <0.001 |
| Male, n (%) | 1131 (65.9) | 167 (53.7) | <0.001 |
| Smoke, n (%) | 211 (12.3) | 25 (8.0) | 0.031 |
| Hypertension, n (%) | 847 (49.3) | 126 (40.5) | <0.001 |
| Diabetes, n (%) | 460 (26.8) | 89 (28.6) | 0.508 |
| Heart failure, n (%) | 636 (37.1) | 148 (47.6) | <0.001 |
| COPD, n (%) | 16 (0.9) | 4 (1.3) | 0.561 |
| Hyperlipidaemia, n (%) | 414 (24.1) | 52 (16.7) | 0.004 |
| Ventricular arrhythmia, n (%) | 285 (16.6) | 76 (24.4) | 0.001 |
| Cerebral infarction, n (%) | 34 (2.0) | 12 (3.9) | 0.041 |
| Admission drugs | |||
| Aspirin, n (%) | 1456 (84.8) | 207 (66.6) | <0.001 |
| Clopidogrel, n (%) | 1123 (65.4) | 122 (39.2) | <0.001 |
| Statin, n (%) | 1278 (74.5) | 129 (41.5) | <0.001 |
| β-blocker, n (%) | 1438 (83.8) | 150 (48.2) | <0.001 |
| ACEI, n (%) | 1148 (66.9) | 66 (21.2) | <0.001 |
| Diuretic, n (%) | 940 (54.8) | 152 (48.9) | 0.055 |
| Insulin, n (%) | 291 (17.0) | 83 (26.7) | <0.001 |
| Laboratory data | |||
| WBC, 109/L | 11.3 (9.0–14.3) | 13.1 (10.8–18.4) | <0.001 |
| Platelet count, 109/L | 219 (174–271） | 219 (167–276) | 0.545 |
| Haemoglobin, mg/dL | 11.8 (10.3–13.3) | 11.2 (9.9–12.1) | <0.001 |
| Sodium, mmol/L | 138 (136–140) | 138 (135–141) | 0.144 |
| Creatinine, mg/dL | 0.9 (0.8–1.2) | 1.4 (1.0–2.0) | <0.001 |
| Urea, mg/dL | 17.0 (13.0–24.0) | 28.0 (18.0–44.0) | <0.001 |
| SOFA score | 2.0 (1.0–5.0) | 7.0 (4.0–10.0) | <0.001 |
| Glucose_0, mg/dL | 136.0 (114.0–175.0) | 164.0 (135.0–252.0) | <0.001 |
Data are mean±SD, median (IQR) or n (%).
ACEI, angiotensin-converting enzyme inhibitor; COPD, chronic obstructive pulmonary disease; Glucose_0, admission blood glucose; SOFA, sequential organ failure assessment; WBC, white blood cell count.